News | Atrial Fibrillation | May 08, 2020

High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients

Results of HRS late-breaking Swiss-AF study provides better understanding of cognitive decline in patients with AF arrhythmia

The Swiss-AF study shows High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients. #Heartrhythm2020 #HRS20 #HRS2020

May 8, 2020 – A new clinical study found that patients with atrial fibrillation (AF) experienced a high incidence of clinically silent brain infarcts, despite taking oral anticoagulants for stroke prevention. Silent brain infarcts were significantly associated withcognitive decline. The results of the Swiss Atrial Fibrillation Cohort (Swiss-AF) trial were presented as a late-breaking clinical trial as part of Heart Rhythm Society (HRS) 2020 Science virtual meeting.

AF patients have a high risk of cognitive dysfunction and dementia, in part due to their high risk of ischemic stroke. To help mitigate the risk of an ischemic stroke, many patients with AF are prescribed oral anticoagulation. Clinically silent brain infarcts can be hard to detect in patients and have a similar impact on cognitive decline as an actual stroke. The incidence of silent brain infarcts in anticoagulated patients and whether they impact cognitive function is currently unknown. The Swiss-AF study sought to better understand the role clinically silent brain infarcts play in cognitive decline in AF patients.

The multicenter observational cohort study enrolled 1,227 patients aged ≥65 with previously documented AF. The mean age at baseline was 71.5 ± 8.4 years, and 26 percent were women. Patients underwent brain magnetic resonance imaging (MRI) at baseline and after two years of follow-up. Brain infarcts were quantified in a central core laboratory. New infarcts were defined as lesions present on the follow-up MRI scan but not at baseline, while clinically silent infarcts were defined as new infarcts in patients without a clinical stroke between the two MRI studies.

In the Swiss-AF study, 84 percent of study participants received oral anticoagulation. Nonetheless, 5.5 percent of the participants had a new brain infarct after two years of follow-up. Of the 68 patients with new brain infarcts, 58 (85 percent) had a clinically silent event, 59 (87) were taking oral anticoagulation during the follow-up period, and 51 (75 percent) had a clinically silent brain infarct while taking oral anticoagulation. Patients with new brain infarcts had a stronger decline in cognitive function than patients without new brain infarcts.

“When it comes to our understanding of the link between clinical stroke and AF, what we have known so far is only the tip of the iceberg. This clinical study set out to understand why AF patients suffer from higher rates of cognitive decline even without experiencing a stroke, and provide the clinical field a better understanding of the impact silent brain lesions have on cognitive decline,” said lead author David Conen, M.D., MPH, Associate Professor in the Division of Cardiology and Department of Medicine at McMaster University. “Although many AF patients benefit from oral anticoagulants, additional treatment might need to be considered in some patients to prevent silent brain infarcts. Our hope is that these results will help physicians advance treatment options for AF management among their patients and help mitigate the risk of cognitive decline, dementia and stroke.”

The authors of this study call for additional trials to further study the long-term consequences and impacts of silent brain infarcts in AF patients. Through additional research, the authors also hope to better understand which risk factors are associated with new silent brain infarcts. 

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

 

Related Content

News | Antiplatelet and Anticoagulation Therapies
October 4, 2021 — One month of dual antiplatelet therapy (DAPT) following stent implantation in high bleeding risk ...
Home October 04, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 — The STOPDAPT-2 ACS trial does not support the use of one month of dual antiplatelet therapy (DAPT) ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

September 1, 2021 – The anticoagulant edoxaban (Savaysa) may be just as effective as warfarin for preventing heart ...

Home September 01, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

June 21, 2021 — The U.S. Food and Drug Administration (FDA) approved Boehringer Ingelheim's dabigatran etexilate ...

Home June 21, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

May 15, 2021 — The ADAPTABLE trial found no significant differences in cardiovascular events or major bleeding in ...

Home May 15, 2021
Home
News | Antiplatelet and Anticoagulation Therapies

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

Home April 28, 2021
Home
Feature | Antiplatelet and Anticoagulation Therapies | By Dave Fornell, Editor

A comprehensive review or more than 80 randomized controlled trials (RCTs) investigating how to best manage optimal ...

Home March 22, 2021
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

Roxana Mehran, M.D., and Marco Valgimiggle, M.D., present the results of the Xience 90/28 trials that evaluated the use ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

Gregg Stone, M.D., presents the results of a pooled analysis of randomized trials of bivalirudin virus heparin in acute ...

Home October 17, 2020
Home
Subscribe Now